QR Code

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

Abstract Introduction Although acute and preventive treatments for migraine are commonly given in combination, data on the real-world effectiveness of ubrogepant as an acute treatment when used with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (with or without onabotulinumtoxin...

Description complète

Enregistré dans:
Auteurs principaux: Richard B. Lipton, Janette Contreras-De Lama, Daniel Serrano, Ella Engstrom, Nicolai D. Ayasse, Weijie Poh, François Cadiou, Aubrey Manack Adams
Format: Artigo
Langue:Inglês
Publié: Adis, Springer Healthcare 2023-11-01
Collection:Neurology and Therapy
Sujets:
CGRP
Effectiveness
Migraine
Real-world
Satisfaction
Ubrogepant
Accès en ligne:https://doi.org/10.1007/s40120-023-00556-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires